» Articles » PMID: 34177966

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor

Overview
Journal Front Immunol
Date 2021 Jun 28
PMID 34177966
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Factor VIII (fVIII) is a procoagulant protein that binds to activated factor IX (fIXa) on platelet surfaces to form the intrinsic tenase complex. Due to the high immunogenicity of fVIII, generation of antibody inhibitors is a common occurrence in patients during hemophilia A treatment and spontaneously occurs in acquired hemophilia A patients. Non-classical antibody inhibitors, which block fVIII activation by thrombin and formation of the tenase complex, are the most common anti-C2 domain pathogenic inhibitors in hemophilia A murine models and have been identified in patient plasmas. In this study, we report on the X-ray crystal structure of a B domain-deleted bioengineered fVIII bound to the non-classical antibody inhibitor, G99. While binding to G99 does not disrupt the overall domain architecture of fVIII, the C2 domain undergoes an ~8 Å translocation that is concomitant with breaking multiple domain-domain interactions. Analysis of normalized B-factor values revealed several solvent-exposed loops in the C1 and C2 domains which experience a decrease in thermal motion in the presence of inhibitory antibodies. These results enhance our understanding on the structural nature of binding non-classical inhibitors and provide a structural dynamics-based rationale for cooperativity between anti-C1 and anti-C2 domain inhibitors.

Citing Articles

Biophysical characterization of blood coagulation factor VIII binding to lipid nanodiscs that mimic activated platelet surfaces.

Avery N, Young I, Lu S, Vaughan J, Korus P, Richardson T J Thromb Haemost. 2024; 23(2):513-524.

PMID: 39549835 PMC: 11786986. DOI: 10.1016/j.jtha.2024.11.003.


Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside.

Evangelidis N, Kotsiou N, Evangelidis P, Alevizopoulos V, Dermitzakis I, Chissan S Curr Issues Mol Biol. 2024; 46(6):5147-5160.

PMID: 38920981 PMC: 11201880. DOI: 10.3390/cimb46060309.


Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hotspot on the C1 domain.

Childers K, Cowper B, Vaughan J, McGill J, Davulcu O, Lollar P J Thromb Haemost. 2024; 22(9):2449-2459.

PMID: 38849084 PMC: 11343672. DOI: 10.1016/j.jtha.2024.05.024.


An intronic RNA element modulates Factor VIII exon-16 splicing.

Tse V, Chacaltana G, Gutierrez M, Forino N, Jimenez A, Tao H Nucleic Acids Res. 2023; 52(1):300-315.

PMID: 37962303 PMC: 10783525. DOI: 10.1093/nar/gkad1034.


SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.

Childers K, Peters S, Lollar P, Spencer H, Doering C, Spiegel P Blood Adv. 2022; 6(11):3240-3254.

PMID: 35255502 PMC: 9198903. DOI: 10.1182/bloodadvances.2021005874.

References
1.
Gilbert G, Arena A . Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem. 1996; 271(19):11120-5. DOI: 10.1074/jbc.271.19.11120. View

2.
Hartholt R, van Velzen A, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J . To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity. Blood Rev. 2017; 31(5):339-347. DOI: 10.1016/j.blre.2017.07.001. View

3.
Bovenschen N, Boertjes R, van Stempvoort G, Voorberg J, Lenting P, Meijer A . Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem. 2003; 278(11):9370-7. DOI: 10.1074/jbc.M212053200. View

4.
Gish J, Jarvis L, Childers K, Peters S, Garrels C, Smith I . Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor. Blood. 2021; 137(21):2981-2986. PMC: 8160500. DOI: 10.1182/blood.2020008940. View

5.
Powell J . Longer-acting clotting factor concentrates for hemophilia. J Thromb Haemost. 2015; 13 Suppl 1:S167-75. DOI: 10.1111/jth.12912. View